TR200003019T1 - İkameli 2-fenil-1-(3,4-dihidroksi-5-nitrofenil)-1-etanonlar, bunları ihtiva eden farmasötik bileşimler - Google Patents

İkameli 2-fenil-1-(3,4-dihidroksi-5-nitrofenil)-1-etanonlar, bunları ihtiva eden farmasötik bileşimler

Info

Publication number
TR200003019T1
TR200003019T1 TR2000/03019T TR200003019T TR200003019T1 TR 200003019 T1 TR200003019 T1 TR 200003019T1 TR 2000/03019 T TR2000/03019 T TR 2000/03019T TR 200003019 T TR200003019 T TR 200003019T TR 200003019 T1 TR200003019 T1 TR 200003019T1
Authority
TR
Turkey
Prior art keywords
ethanones
nitrophenyl
dihydroxy
phenyl
substituted
Prior art date
Application number
TR2000/03019T
Other languages
English (en)
Inventor
Benes Jan
Manuel Viera Araujo Soares Da Silva Patricio
Alexander Learmonth David
Original Assignee
Portela & C.A., S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portela & C.A., S.A. filed Critical Portela & C.A., S.A.
Publication of TR200003019T1 publication Critical patent/TR200003019T1/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/39—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by esterified hydroxy groups
    • C07C205/42—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by esterified hydroxy groups having nitro groups or esterified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/43—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by esterified hydroxy groups having nitro groups or esterified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/59—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/56—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and doubly-bound oxygen atoms bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
    • C07C45/29—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups
    • C07C45/292—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups with chromium derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/46—Friedel-Crafts reactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Formül I'e uygun yeni terkipler bazi merkezi ve çevresel sinir sistemi bozukluklarinin tedavisinde, katekolaminlerin 0-metilasyonunun azaltilmasinin tedaviye yönelik bir fayda saglayabilecegi durumlarda son derece etkili farmasötik özelliklere sahiptirler. Bu hastaliklara örnek olarak Parkinson hastaligi, parkinsona ait bozukluklar, sindirim sistemi rahatsizliklari, ödem ve yüksek tansiyon verilebilir.
TR2000/03019T 1998-12-18 1999-12-17 İkameli 2-fenil-1-(3,4-dihidroksi-5-nitrofenil)-1-etanonlar, bunları ihtiva eden farmasötik bileşimler TR200003019T1 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9827996A GB2344819A (en) 1998-12-18 1998-12-18 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones

Publications (1)

Publication Number Publication Date
TR200003019T1 true TR200003019T1 (tr) 2001-02-21

Family

ID=10844561

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/03019T TR200003019T1 (tr) 1998-12-18 1999-12-17 İkameli 2-fenil-1-(3,4-dihidroksi-5-nitrofenil)-1-etanonlar, bunları ihtiva eden farmasötik bileşimler

Country Status (20)

Country Link
US (1) US6512136B1 (tr)
EP (1) EP1010688B1 (tr)
CN (1) CN1173926C (tr)
AR (1) AR021893A1 (tr)
AT (1) ATE236870T1 (tr)
AU (1) AU754113B2 (tr)
BR (1) BR9908084B1 (tr)
CA (1) CA2292968C (tr)
CZ (1) CZ297919B6 (tr)
DE (1) DE69906671T2 (tr)
DK (1) DK1010688T3 (tr)
ES (1) ES2197583T3 (tr)
GB (1) GB2344819A (tr)
HU (1) HU226396B1 (tr)
PL (1) PL193998B1 (tr)
PT (1) PT1010688E (tr)
RU (1) RU2232748C2 (tr)
SI (1) SI1010688T1 (tr)
TR (1) TR200003019T1 (tr)
WO (1) WO2000037423A1 (tr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0015228D0 (en) * 2000-06-21 2000-08-16 Portela & Ca Sa Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders
GB2377934B (en) 2001-07-25 2005-01-12 Portela & Ca Sa Method for the nitration of phenolic compounds
FI20012242A0 (fi) * 2001-11-19 2001-11-19 Orion Corp Uudet farmaseuttiset yhdisteet
WO2004100929A1 (en) 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
WO2005025561A1 (en) * 2003-09-04 2005-03-24 Synergia Pharma, Inc. Compositions and methods for orthostatic intolerance
WO2006037061A2 (en) * 2004-09-28 2006-04-06 Farouk Karoum Compositions and methods of using d-dopa to treat parkinson's disease
MY148644A (en) * 2005-07-18 2013-05-15 Orion Corp New pharmaceutical compounds
AU2006272978B2 (en) 2005-07-26 2012-06-07 Bial - Portela & Ca, S.A. Nitrocatechol derivatives as COMT inhibitors
EP1764095A1 (en) * 2005-09-20 2007-03-21 Revotar Biopharmaceuticals AG Novel nitrocatechol derivatives having selectin ligand activity
US20090012177A1 (en) * 2006-03-23 2009-01-08 Rahim Shafa Treatment of psychiatric disorders using entacapone, tolcapone and other COMT inhibitor or MB-COMT inhibitor drugs
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
EP2363124B1 (en) 2006-06-28 2016-02-17 Lundbeck NA Ltd Pharmaceutical compositions comprising droxidopa
CN101631548B (zh) * 2007-01-31 2014-08-27 比艾尔-坡特拉有限公司 Comt抑制剂的单次药物剂量单元和药物组合物
AU2008226541B2 (en) * 2007-03-09 2013-05-09 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia
EP2514417A3 (en) 2007-05-07 2013-01-30 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
CA2708281A1 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
EP2259777A2 (en) * 2008-02-28 2010-12-15 BIAL - Portela & Ca., S.A. Pharmaceutical composition for poorly soluble drugs
AU2009226221A1 (en) 2008-03-17 2009-09-24 Bial - Portela & Ca., S.A. Crystal forms of 5- [3- (2, 5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl) [1,2,3] oxadiazol-5-yl] -3-nit robenzene-1, 2-diol
JP5864410B2 (ja) * 2009-04-01 2016-02-17 ノヴィファーマ ソシエテ アノニム ニトロカテコール誘導体を含む医薬製剤及びその製造方法
KR102023255B1 (ko) * 2009-04-01 2019-09-19 바이알 - 포르텔라 앤드 씨에이 에스에이 니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법
TW201107303A (en) * 2009-05-27 2011-03-01 Sanofi Aventis Process for the production of benzofurans
KR101868326B1 (ko) 2010-03-04 2018-06-19 오리온 코포레이션 파킨슨병의 치료를 위한 레보도파, 카르비도파 및 엔타카폰의 용도
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤
BR112014014341A2 (pt) 2011-12-13 2017-08-22 Bial Portela & Ca Sa Intermediário metilado, seu método de preparação e seus usos, e composição farmacêutica
WO2013116325A1 (en) 2012-01-31 2013-08-08 Chelsea Therapeutics, Inc. Improving postural stability administering droxidopa
TWI638802B (zh) 2012-05-24 2018-10-21 芬蘭商奧利安公司 兒茶酚ｏ－甲基轉移酶活性抑制化合物
WO2014147464A2 (en) * 2013-03-20 2014-09-25 Ra Chem Pharma Limited Novel process for the preparation of tolcapone
WO2016083863A1 (en) 2014-11-28 2016-06-02 Bial - Portela & Ca, S.A. Medicaments for slowing parkinson's disease
CN111902386A (zh) * 2017-12-28 2020-11-06 瑞璞鑫(苏州)生物科技有限公司 作为fto抑制剂的苯基甲酮衍生物
EP3972971A1 (en) * 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK175069B1 (da) * 1986-03-11 2004-05-24 Hoffmann La Roche Pyrocatecholderivater
YU213587A (en) * 1986-11-28 1989-06-30 Orion Yhtymae Oy Process for obtaining new pharmacologic active cateholic derivatives
RU2004536C1 (ru) * 1991-05-30 1993-12-15 Новосибирский институт органической химии СО РАН Способ получени мускус-кетона

Also Published As

Publication number Publication date
DK1010688T3 (da) 2003-08-04
BR9908084B1 (pt) 2009-12-01
AU754113B2 (en) 2002-11-07
PL193998B1 (pl) 2007-04-30
DE69906671D1 (de) 2003-05-15
EP1010688A1 (en) 2000-06-21
ES2197583T3 (es) 2004-01-01
CZ297919B6 (cs) 2007-04-25
CN1173926C (zh) 2004-11-03
CA2292968C (en) 2009-05-19
GB9827996D0 (en) 1999-02-10
CN1296471A (zh) 2001-05-23
DE69906671T2 (de) 2004-03-04
RU2232748C2 (ru) 2004-07-20
SI1010688T1 (en) 2003-10-31
BR9908084A (pt) 2000-10-24
ATE236870T1 (de) 2003-04-15
HUP0100786A2 (hu) 2001-08-28
US6512136B1 (en) 2003-01-28
CZ20003018A3 (cs) 2000-12-13
AU1873100A (en) 2000-07-12
AR021893A1 (es) 2002-08-07
EP1010688B1 (en) 2003-04-09
PT1010688E (pt) 2003-08-29
PL342542A1 (en) 2001-06-18
WO2000037423A1 (en) 2000-06-29
HUP0100786A3 (en) 2002-12-28
GB2344819A (en) 2000-06-21
CA2292968A1 (en) 2000-06-18
HU226396B1 (en) 2008-11-28

Similar Documents

Publication Publication Date Title
HUP0100786A2 (hu) Helyettesített 2-fenil-1-(3,4-dihidroxi-5-nitrofenil)-1-etanonok, felhasználásuk egyes központi és perifériás idegrendszeri betegségek kezelésére és e vegyületeket tartalmazó gyógyszerkészítmények
MY137348A (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
DE69842151D1 (de) CHINOLIN UND CHINOXALINVERBINDUNGEN DIE DEN VON BLUTPLÄTTCHEN ABSTAMMENDEN FAKTOR UND/ODER p56Ick-TYROSINKINASE HEMMEN
NO20101190L (no) Anvendelse av buprenorfin i fremstillingen av et medikament
NO20044475L (no) 2-(2,6-diklorfenyl)-diarulimidazoler
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ATE410506T1 (de) Behandlung der pompeschen krankheit
EA200000723A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
TR199800258T1 (tr) Yeni opioid peptidler.
KR960700742A (ko) 아토피성질환 치료약(atopic disease remedy)
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
AP2004003069A0 (en) 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof.
DE69822665D1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
DE69507029D1 (de) Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin-vermittelten krankheiten
UY26130A1 (es) Compuestos para tratar la obesidad
BR0213540A (pt) Compostos, método para o tratamento de enfermidades ou distúrbios em um paciente e composição farmacêutica que compreende os mesmos
TR200101649T2 (tr) Piperazin türevleri.
BR0312294A (pt) Arilcarbonil piperazinas e hteroarilcarbonilpiperazinas e o uso das mesmas para tratamento de doenças benignas e malignas
DE602004023762D1 (de) Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren
UY27451A1 (es) 2,5-diamidoindoles sustituidos y su utilización
DE69928521D1 (de) Cabergolin und pramipexol zur behandlung von krankheiten des zentralnervensystems, insbesondere parkinsonscher krankheit
AU9139791A (en) Use of quisqualate-receptor antagonists for treating Parkinson's disease
RU95110774A (ru) Олигонуклеотиды, терапевтические композиции, применение композиций
BR9916417A (pt) Compostos triazinaona para tratamento de doenças devidas à sarcosystis, neospora e toxoplasma
DE69510933D1 (de) Amidderivate und ihre therapeutische anwendung